Market Cap 6.39B
Revenue (ttm) 130.13M
Net Income (ttm) -260.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.26%
Debt to Equity Ratio 0.00
Volume 532,000
Avg Vol 730,366
Day's Range N/A - N/A
Shares Out 66.42M
Stochastic %K 1%
Beta 2.23
Analysts Strong Sell
Price Target $111.93

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
Quantumup
Quantumup Sep. 10 at 6:13 PM
Baird reiterated $SLNO Outperform/$121. Baird said: No change to outlook on FAERS update. The FAERS database was updated and now tragically has a listed death due to pulmonary embolism in a patient who was 17 years old, which management noted in an 8-K was considered by the physician to be not related to Vykat XR. Given comorbidities likely increasing baseline risk (lymphedema, superficial thrombophlebitis, obesity) and the physician's report as unrelated, we think the selloff here is far overdone and presents an even more attractive opportunity for investors to buy the launch on sale. $AARD $RYTM $ACAD $BIIB
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:54 PM
TD Cowen reiterated $SLNO Buy/$120. TD Cowen said in its note: Three new SAEs for Vykat XR were uploaded to the FAERS database, which included a highly unfortunate death related to pulmonary embolism. The reporting physician does not consider this event as treatment-related, and $SLNO's assessment is the same. Pulmonary embolism risk is significantly increased in PWS and obese patients, and per our dinner with management last night, safety remains consistent. $AARD $RYTM $ACAD $BIIB
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 10 at 4:23 PM
$SLNO i'm not that surprised by today's dip. retracing from overbought bullish sentiment post-approval/launch + upcoming potential competition $ACAD $HRMY $RYTM
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 11:25 AM
$RYTM Really good write-up that perfectly summarizes RYTM's present situation. So if you want to bring your RYTM knowledge up to date or just discover RYTM, this is required reading. https://beyondspx.com/quote/RYTM/analysis/rhythm-pharmaceuticals-unlocking-a-new-era-of-growth-in-rare-obesity-nasdaq-rytm
0 · Reply
profitraider
profitraider Sep. 7 at 5:53 PM
$RYTM It’s over Boyz… the good times are over! Went on for way too long!! Too risky now 👍
1 · Reply
abcdzepeda
abcdzepeda Sep. 6 at 11:17 PM
$RYTM What’s the deal with this after hours decline? Did I miss something?
0 · Reply
chrsc
chrsc Sep. 2 at 5:39 PM
$RYTM 52 week high on a very red day. very impressive.
1 · Reply
abcdzepeda
abcdzepeda Sep. 2 at 3:53 PM
$RYTM i’m calling it! $110 by September 24, and after that conference call, I would not be surprised to see another $10 increase.
0 · Reply
Im_not_Mr_Lebowski
Im_not_Mr_Lebowski Aug. 26 at 12:51 AM
$RYTM @50bps @Monkey_Banana_Genius @Doozio @MaverikIT @rxptgh @JasonCO FML. Lol. 🤮
1 · Reply
abcdzepeda
abcdzepeda Aug. 22 at 3:06 PM
$RYTM Timing is everything, after Jerome Powell’s speech today everything is pointing towards a rate cut in September. This is going to set us up nicely, because we have a conference call on September 24 for investors to hear the game plan for the launch of HO in the US and in EU. When the rate cuts begin, our economy is going to boom. And investors will be eager to invest in a company like rhythm who is also booming. I don’t know if we will be bought out., Because it would require a huge amount of money to buy us out. Bottom line is that we are in for a very interesting ride! Have an awesome weekend rhythmites!
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25, 2025, 11:21 AM EST - 7 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven


Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Nov 13, 2024, 4:01 PM EST - 10 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants


Quantumup
Quantumup Sep. 10 at 6:13 PM
Baird reiterated $SLNO Outperform/$121. Baird said: No change to outlook on FAERS update. The FAERS database was updated and now tragically has a listed death due to pulmonary embolism in a patient who was 17 years old, which management noted in an 8-K was considered by the physician to be not related to Vykat XR. Given comorbidities likely increasing baseline risk (lymphedema, superficial thrombophlebitis, obesity) and the physician's report as unrelated, we think the selloff here is far overdone and presents an even more attractive opportunity for investors to buy the launch on sale. $AARD $RYTM $ACAD $BIIB
0 · Reply
Quantumup
Quantumup Sep. 10 at 5:54 PM
TD Cowen reiterated $SLNO Buy/$120. TD Cowen said in its note: Three new SAEs for Vykat XR were uploaded to the FAERS database, which included a highly unfortunate death related to pulmonary embolism. The reporting physician does not consider this event as treatment-related, and $SLNO's assessment is the same. Pulmonary embolism risk is significantly increased in PWS and obese patients, and per our dinner with management last night, safety remains consistent. $AARD $RYTM $ACAD $BIIB
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 10 at 4:23 PM
$SLNO i'm not that surprised by today's dip. retracing from overbought bullish sentiment post-approval/launch + upcoming potential competition $ACAD $HRMY $RYTM
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 11:25 AM
$RYTM Really good write-up that perfectly summarizes RYTM's present situation. So if you want to bring your RYTM knowledge up to date or just discover RYTM, this is required reading. https://beyondspx.com/quote/RYTM/analysis/rhythm-pharmaceuticals-unlocking-a-new-era-of-growth-in-rare-obesity-nasdaq-rytm
0 · Reply
profitraider
profitraider Sep. 7 at 5:53 PM
$RYTM It’s over Boyz… the good times are over! Went on for way too long!! Too risky now 👍
1 · Reply
abcdzepeda
abcdzepeda Sep. 6 at 11:17 PM
$RYTM What’s the deal with this after hours decline? Did I miss something?
0 · Reply
chrsc
chrsc Sep. 2 at 5:39 PM
$RYTM 52 week high on a very red day. very impressive.
1 · Reply
abcdzepeda
abcdzepeda Sep. 2 at 3:53 PM
$RYTM i’m calling it! $110 by September 24, and after that conference call, I would not be surprised to see another $10 increase.
0 · Reply
Im_not_Mr_Lebowski
Im_not_Mr_Lebowski Aug. 26 at 12:51 AM
$RYTM @50bps @Monkey_Banana_Genius @Doozio @MaverikIT @rxptgh @JasonCO FML. Lol. 🤮
1 · Reply
abcdzepeda
abcdzepeda Aug. 22 at 3:06 PM
$RYTM Timing is everything, after Jerome Powell’s speech today everything is pointing towards a rate cut in September. This is going to set us up nicely, because we have a conference call on September 24 for investors to hear the game plan for the launch of HO in the US and in EU. When the rate cuts begin, our economy is going to boom. And investors will be eager to invest in a company like rhythm who is also booming. I don’t know if we will be bought out., Because it would require a huge amount of money to buy us out. Bottom line is that we are in for a very interesting ride! Have an awesome weekend rhythmites!
0 · Reply
TeeMan123
TeeMan123 Aug. 22 at 2:02 PM
$RYTM we being bought out or something!?!?
0 · Reply
KingofStocksAce
KingofStocksAce Aug. 21 at 11:38 PM
$RYTM +3,000% since. It was a gem…
2 · Reply
abcdzepeda
abcdzepeda Aug. 21 at 8:02 PM
$RYTM way to close it out!
0 · Reply
abcdzepeda
abcdzepeda Aug. 21 at 3:58 PM
0 · Reply
TeeMan123
TeeMan123 Aug. 21 at 2:46 PM
$RYTM GIVE US $100!!!!!!!!!!!!!!!!!!!!
1 · Reply
biolover
biolover Aug. 21 at 12:53 PM
$GPCR $RYTM $SLNO $VKTX RYTM drug total rip off $ 400,000-500000 per year for wt loss in syndrome obesity. This is how the health care operates. Obviously supported by many bio hedge funds hoping for BO. I don’t believe this malfunctioning price disparity will last.
1 · Reply
Quantumup
Quantumup Aug. 21 at 12:38 PM
Citizens reiterated $RYTM Market Outperform-$135 and said: We are pleased that the FDA accepted the sNDA and the Priority Review speaks to the unmet need and strength of the setmelanotide submission. LLY $VKTX NVO $GPCR TERN $AARD $SLNO Citizens added:
0 · Reply
wrengler4
wrengler4 Aug. 21 at 11:16 AM
$AGIO $QURE check out the history of Matt Kapusta at QURE and his selling of options in 2021, 2022 and 2023 in the 30’s , much like the antics of goof ball GOFF, here … No investor makes money , due to there inabilities to create value , but the bozos sell each chance they get !! GOFF DOESNT GIVE A FCUK ..it is the MATT KAPUSTA theory : MILK THE SOB as long as you can before they oust you for : poor performance for inside fund shareholders !!! GOFF has brought no value in 3 years this month ! FOUSE NEVER DID !!! she created a NEW HISTORIC LOW $16.95 from $62.10 !!!! ( but she was always a loser from Bunge and discarded from Celgene , but was David Schenkien’s girl,Friday ) The game is the same with these two losers , Kapusta and Goff !!! David Meeker , $RYTM, are you reading this ??? Your RYTM was $3 in 2023, today $98 !!! Guess one knows , WHO is with creating value and WHOM ARE NOT !!!!
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 21 at 9:53 AM
WATCHLIST AUG 21 2025. $RYTM Rhythm Pharmaceuticals Announces The FDA Has Accepted Its Supplemental New Drug Application For Setmelanotide To Treat Acquired Hypothalamic Obesity $MSW Ming Shing Group Enters Into A Bitcoin Purchase Agreement With Winning Mission Group Limited For The Purchase Of 4,250 Bitcoins $BZ Jefferies Maintains Buy on Kanzhun, Raises Price Target to $24 $CNVS Cineverse And ElementalTV Form Strategic Partnership To Enhance Streaming Reach With Advanced Audience Intelligence And Identity Resolution $LTH Life Time Launches Melatonin-Free Sleep Supplement 'LTH Dream' With Triple Magnesium Blend For Restful, Grogginess-Free Sleep
0 · Reply
abcdzepeda
abcdzepeda Aug. 20 at 8:43 PM
$RYTM it looks like all us rhythmites are going to have an awesome Christmas! Hold onto your hat, folks, because we are in for an awesome ride from now until December.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 20 at 8:12 PM
$RYTM No FDA-approved therapies currently exist for acquired hypothalamic obesity. First in class!!!!
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 20 at 8:11 PM
$RYTM very bullish ~20% BMI reduction vs placebo in acquired hypothalamic obesity — very strong efficacy in both adults and children.
0 · Reply